IL299212A - Preparations for the treatment of respiratory arrest during sleep - Google Patents

Preparations for the treatment of respiratory arrest during sleep

Info

Publication number
IL299212A
IL299212A IL299212A IL29921222A IL299212A IL 299212 A IL299212 A IL 299212A IL 299212 A IL299212 A IL 299212A IL 29921222 A IL29921222 A IL 29921222A IL 299212 A IL299212 A IL 299212A
Authority
IL
Israel
Prior art keywords
minutes
thc
pharmaceutically acceptable
acceptable salt
carbonic anhydrase
Prior art date
Application number
IL299212A
Other languages
English (en)
Hebrew (he)
Inventor
Robert BLEACKLEY Mark
Agarwal Sudhanshu
Bradley LATHAM Joel
Original Assignee
Incannex Healthcare Ltd
Robert BLEACKLEY Mark
Agarwal Sudhanshu
Bradley LATHAM Joel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by Incannex Healthcare Ltd, Robert BLEACKLEY Mark, Agarwal Sudhanshu, Bradley LATHAM Joel filed Critical Incannex Healthcare Ltd
Publication of IL299212A publication Critical patent/IL299212A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL299212A 2020-07-09 2021-07-09 Preparations for the treatment of respiratory arrest during sleep IL299212A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (1)

Publication Number Publication Date
IL299212A true IL299212A (en) 2023-02-01

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299212A IL299212A (en) 2020-07-09 2021-07-09 Preparations for the treatment of respiratory arrest during sleep

Country Status (8)

Country Link
US (1) US20230310364A1 (enExample)
EP (1) EP4178568A4 (enExample)
JP (1) JP7796718B2 (enExample)
AU (1) AU2021306424A1 (enExample)
CA (1) CA3182528A1 (enExample)
CO (1) CO2023000118A2 (enExample)
IL (1) IL299212A (enExample)
WO (1) WO2022006636A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023289652A1 (en) * 2022-06-21 2024-12-12 Apnimed, Inc. (Delaware) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
AU2023404665A1 (en) * 2022-11-29 2025-07-17 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
EP3746068A4 (en) * 2018-01-29 2021-11-03 Evero COMPOSITIONS AND METHODS OF TREATMENT FOR OBSTRUCTIVE SLEEP APNEA
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
CN117177741A (zh) * 2021-04-16 2023-12-05 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合

Also Published As

Publication number Publication date
AU2021306424A1 (en) 2023-01-19
CA3182528A1 (en) 2022-01-13
JP7796718B2 (ja) 2026-01-09
JP2023533289A (ja) 2023-08-02
US20230310364A1 (en) 2023-10-05
EP4178568A4 (en) 2024-10-16
WO2022006636A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17
CO2023000118A2 (es) 2023-04-17

Similar Documents

Publication Publication Date Title
US20230310364A1 (en) Compositions and methods for the treatment of obstructive sleep apnoea (osa)
TWI819995B (zh) 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法
EP4291170B1 (en) Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
KR20220145377A (ko) 5ht2a 효능제 투여 후의 제어 효과
IL301910A (en) Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
CN114555166A (zh) 神经元可塑性的刺激
IL303388A (en) Treatment of refractory convulsions
RU2563821C2 (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
EP4322930A1 (en) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
CN114507205A (zh) 二氢杨梅素四氢吡咯复合物及其制备方法和应用
EP4522271A1 (en) Methods of use of t-type calcium channel modulators
CN117580579A (zh) 用于治疗儿科患者的癫痫发作病症的方法和组合物
WO2023000247A1 (zh) α-细辛脑在制备预防或治疗出血性脑卒中药物中的应用
Goswami et al. Intranasal ketamine for acute pain: behavioral and neurophysiological safety analysis in mice
KR20230159462A (ko) 수면 무호흡증 치료 방법 및 조성물
IL305289A (en) Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
AU2023404665A1 (en) A method of treating obstructive sleep apnoea (osa)
Fantini et al. Sleep and violence
TWI739220B (zh) 包含克拉維酸與丙戊酸之組合物及其用途
WO2025107039A1 (en) Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
KR20260056192A (ko) 발작 치료 방법
WO2025208209A1 (en) Use of ibogaine in the treatment of central nervous system stroke
CN122070918A (zh) 哌甲酯在制备创伤后应激障碍（ptsd）心理治疗增效剂中的应用
CN116782891A (zh) 大麻二酚对难治性癫痫发作的治疗
JPWO2005027968A1 (ja) ダウン症候群治療剤